Excitingly, multiple FDA-approved IL-17 monoclonal antibodies are available for the treatment of psoriasis, and the slightly higher associated risks of all-cause dementia in individuals with psoriasis (25, 26) provide motivation to possibly repurpose these compounds in therapeutic strategies for dementia. Here, IL17A is linked to psoriasis.